There is provided a decoy transcript derived from a ssRNA virus (WV), the transcript comprising at least one of a 5′UTR of the WV, a genomic packaging signal (GPS) of the WV, a 3′UTR of the WV, and an exogenous stop codon.

The invention relates to agents, compositions, uses and methods of a new variant of the infectious bronchitis-virus (IB-virus).

The present invention is drawn to liquid stable poultry vaccines that comprise avian virus. The invention is also drawn to the manufacture of such vaccines methods of vaccinating animal subjects with these vaccines.

Method for producing a defective interfering viral genome (DVG), defective interfering particles comprising the DVG, and methods and uses thereof.

This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.

The present invention provides the isolation and characterization of a new infectious bronchitis virus (IBV) variant, the IBV GA-13 variant, and the production of attenuated isolates thereof, including, but not limited to, the attenuated IBV GA13 isolate 103505 Kd E86, and the use of such IBV isolates in materials and methods for combating infectious bronchitis virus in poultry and reducing the economic impact that infectious bronchitis disease has on poultry production.

The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.

The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.

The invention relates to a mutant Porcine Epizootic Diarrhea Virus (PEDVdN), to methods of producing said PEDVdN, and to compositions comprising the PEDVdN. The invention further relates to methods of stimulating an immune response in a pig comprising administering the PEDVdN, to vaccines comprising the PEDVdN, and to methods for preventing or ameliorating porcine epizootic diarrhoea in a pig.